<DOC>
	<DOCNO>NCT01159353</DOCNO>
	<brief_summary>Primary Objective : - To assess effect insulin glulisine post-prandial plasma glucose excursion first hour standard meal comparison insulin aspart obese subject type 2 diabetes . Secondary Objectives : Pharmacodynamic objective : - To assess effect insulin glulisine postprandial plasma glucose excursion 6 hour standard meal comparison insulin aspart . Pharmacokinetic objective : - To assess post-prandial plasma insulin excursion standard meal , treatment group Safety objective : - To assess safety insulin glulisine comparison insulin aspart</brief_summary>
	<brief_title>Pharmacodynamic Pharmacokinetic Effects Insulin Glulisine Obese Subjects With Type 2 Diabetes After Standard Meal Comparison Insulin Aspart</brief_title>
	<detailed_description>Duration treatment : two study day separate 7-day wash-out period Duration observation : - screen period 1-2 week , &gt; 2 study day ( wash-out period 7 day study day ) , - Follow-up visit ( within 2 week end study treatment period ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>patient type 2 diabetes least one year treat oral antidiabetic agent ( OADs ) least 6 month Baseline Cpeptide â‰¥0.1 nmol/L BMI ( body mass index ) 30 40 kg/m2 HbA1c ( glycosylated hemoglobin ) &lt; 8.5 % sign informed consent type I diabetes mellitus current treatment insulin pregnant breastfeed woman medication know influence insulin sensitivity current treatment systemic corticosteroid history acute metabolic complication past 3 month recurrent severe hypoglycaemia hypoglycaemic unawareness active proliferative diabetic retinopathy know diabetic gastroparesis impair hepatic function , show limited ALT AST 2 time upper limit normal clinically relevant illness nephropathy impair renal function show clearance &lt; 30 ml/min history presence clinically relevant abnormality , medical condition ( cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic , hematological , neurologic , psychiatric , systemic , ocular infectious disease ; acute infectious disease sign acute illness make implementation protocol interpretation result difficult hypersensitivity insulin insulin analog The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>